Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: A pilot study

Angiology

Volumn 63, Issue 6, 2012, Pages 429-434

  Muldowney III, James A S ^a   Chen, Qingxia ^a   Blakemore, Dana L ^a   Vaughan, Douglas E ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

C reactive protein; fibrinolysis; inflammation; pentoxifylline; plasminogen activator inhibitor 1

Indexed keywords

C REACTIVE PROTEIN; PENTOXIFYLLINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOATING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOKINE RELEASE; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OBESITY; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862732457     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712436755     Document Type: Article

References (33)

1. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39(10):1044-1048. (Pubitemid 20351262)
2. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78(1):656-660. (Pubitemid 27289322)
3. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60(3):491-494. (Pubitemid 19023748)
4. van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, van Hinsbergh VW. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost. 1988;60(1):63-67.
5. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Investig. 1996;97(1):37-46.
6. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol. 2000;20(6):1682-1687. (Pubitemid 30353905)
7. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000;24(suppl 4):S23-S27.
8. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69(1):209-216.
9. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313(25):1557-1563. (Pubitemid 16177394)
10. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation. 1995;91(2):284-290.
11. Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance. Diabetes Metab. 1991;17(1 Pt 2):96-100.
12. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Investig. 1995;95(3):995-1001.
13. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989;264(18):10396-10401. (Pubitemid 19161600)
14. Brown NJ, Agirbasli MA,Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998;32(6):965-971. (Pubitemid 29001421)
15. Cigolini M, Tonoli M, Borgato L, et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis. 1999;143(1):81-90. (Pubitemid 29138705)
16. Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol. 2006;24(5):580-583. (Pubitemid 44911255)
17. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104(1):66-72. (Pubitemid 13114585)
18. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology. 1976;27(3):188-196.
19. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV, Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology. 2002;53(5):509-520.
20. Greenberg S, Xie J, Wang Y, et al. Tumor necrosis factor-alpha inhibits endothelium-dependent relaxation. J Appl Physiol. 1993;74(5):2394-2403. (Pubitemid 23157066)
21. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731-733. (Pubitemid 28391836)
22. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45(12):2136-2141.
23. Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl. 1990;10:3-9. (Pubitemid 20091388)
24. Wei W, Parvin N, Tsumura K, et al. Induction of C-reactive protein, serum amyloid P component, and kininogens in the submandibular and lacrimal glands of rats with experimentally induced inflammation. Life Sci. 2001;69(3):359-368. (Pubitemid 32601920)
25. Hou B, Eren M, Painter CA, et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem. 2004; 279(18):18127-18136. (Pubitemid 38623225)
26. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(2):254-257.
27. Fernandes JL, de Oliveira RT, Mamoni RL, et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - a randomized placebo-controlled study. Atherosclerosis. 2008;196(1):434-442.
28. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977. (Pubitemid 13080473)
29. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan- Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46(5):860-867. (Pubitemid 27188265)
30. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation. 1997;96(2):442-447. (Pubitemid 27329418)
31. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003;34(12):2922-2929. (Pubitemid 37517770)
32. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009;25(8):1973-1983.
33. Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb. 2008;15(1):34-40.